Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
AstraZeneca’s COVID Antibody, Daiichi’s TROP2 ADC, and More Up for Review on Dec. 6
A key health ministry advisory panel will discuss whether to recommend approval for a batch of new medicines on December 6, including AstraZeneca’s sipavibart, a long-acting antibody for the pre-exposure prophylaxis of COVID-19 in immunocompromised patients. A total of nine…
To read the full story
Related Article
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- Janssen Files Bispecific Teclistamab for MM in Japan
May 23, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Sanofi Files High-Dose Quadrivalent Flu Vaccine in Japan
December 20, 2023
REGULATORY
- MHLW Proposes Upping Copay Limits in High-Cost Medical Expense Scheme
November 25, 2024
- Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
- AstraZeneca’s COVID Antibody, Daiichi’s TROP2 ADC, and More Up for Review on Dec. 6
November 25, 2024
- Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
- Pharma Pushes to Scrap Off-Year Revisions; LDP Members Urge Fresh Talks by 4 Ministers
November 22, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…